India · Delayed Price · Currency is INR Alkem Laboratories Earnings Call Transcripts
Fiscal Year 2026
-
Q3 FY26 saw 10.7% revenue growth and stable margins, with strong international sales and robust chronic segment performance. Major Medtech acquisition (Occlutech) positions the company for global expansion, targeting 14% CAGR and higher EBITDA margins.
-
Q2 FY26 saw record revenue growth of 17.2% YoY, strong EBITDA margin at 23%, and robust performance across India, US, and international markets. Guidance remains for double-digit growth and margin expansion, with ongoing investments in CDMO and MedTech businesses.
-
Q1 FY 2026 saw double-digit revenue and profit growth, margin expansion, and outperformance in key therapies. Management maintains guidance, expects continued margin improvement, and is investing in new businesses and acquisitions to drive future growth.
Fiscal Year 2025
-
Q4 FY25 saw strong India growth and improved margins, with full-year revenue up 2.3% and net profit up 20.6%. FY26 guidance includes stable 19.5% EBITDA margin, increased R&D spend, and mid-single-digit US growth. CapEx for FY26 is planned at INR 700-750 crore.
-
Q3 and nine-month FY25 saw improved profitability, with EBITDA margins rising on cost controls and higher-margin focus. Domestic growth matched the market, while US and non-US segments faced price and currency pressures. Two strategic acquisitions and robust cash position support future growth.
-
Profitability improved on strategic cost control and high-margin focus, with EBITDA margin up to 21.1% and net profit rising 36% year-over-year. Domestic growth guidance remains 8%-9%, while US business faces mid-single-digit erosion but expects H2 recovery.
-
EBITDA margin rose to 20.1% in Q1 FY25, driven by product mix, cost control, and API pricing. Full-year EBITDA margin guidance is 18%, with gross margin expected at 62%-62.5%. Investments in CDMO and medical devices will impact margins, while domestic and international businesses are set for steady growth.